←Anxiety Disorders
Study register · detail RCT (double-blind) · Anxiety Disorders · 2019

Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders

Masataka et al. ·Frontiers in Psychology Impact 3.2
Clear benefit GRADE Moderate 193 citations
Samplen = 37 Pat.
Duration4 weeks
ControlPlacebo daily orally
EndpointLSAS
Blindingdoppelblind
DesignRCT (double-blind)
Cannabinoidcbd
Max. dose300.0 mg
Routeoral
Key finding

300 mg CBD daily significantly reduced social anxiety symptoms in teenagers compared to placebo.

Summary

n=37 Japanese adolescents (18-19 years) with social anxiety disorder and avoidant personality disorder, double-blind randomized: 300 mg CBD daily (n=17) vs. placebo (n=20) over 4 weeks. CBD significantly reduced anxiety on the Fear of Negative Evaluation Questionnaire and the Liebowitz Social Anxiety Scale (p<0.05). CBD could be a useful option for treating social anxiety.

P
PopulationJapanese teenagers (18–19 years) with social anxiety disorder (SAD) and anxious-avoidant personality disorder, n=37
I
InterventionCannabis oil with 300 mg CBD orally daily, 4 weeks (n=17)
C
ControlPlacebo daily orally (n=20)
O
OutcomeCBD significantly reduced anxiety symptoms on both scales (FNE and LSAS) vs. placebo
Confidence in the evidence
Moderate

The third of four GRADE levels, the effect estimate is probably reliable.

Downgraded for
Imprecision
Quality profile
Sample size ★★★★★
Blinding Double-blind
Effect size Clear benefit
Citations / year ★★★★★
Authors
Masataka N
DOI 10.3389/fpsyg.2019.02466↗
Design: RCT (double-blind)
Share
Indication
Further studies on Anxiety Disorders
All studies →
S Whiting et al. · 2015 · JAMA
2103 citations
Cannabinoids for Medical Use
Mixed

Umfassende SR über 79 RCTs (n=6.462) zu medizinischem Cannabis; KEINE ausreichende Evidenz für Angststörungen als primäres Outcome — moderate Evidenz nur für Schmerz und MS-Spastik, Angst nur als sekundäres/exploratives Outcome in einigen Studien.

10.1001/jama.2015.6358 View study →
A Kedzior et al. · 2014 · BMC psychiatry
299 citations
A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population--a meta-analysis of 31 studies.
Clear benefit Meta-Analyse

Meta-Analyse über k=31 Studien (n≈112.000) zur Assoziation zwischen Angststörungen und Cannabis-Konsum. Kleine positive Assoziation: Angst↔Cannabis-Konsum OR=1.24 (95% CI: 1.06-1.45, p=0.006), Angst↔Cannabis Use Disorder OR=1.68 (95% CI: 1.23-2.31, p=0.001). Prospektive Subgruppe (k=5): Baseline-Cannabis-Konsum prädiziert Follow-up-Angst OR=1.28 (95% CI: 1.06-1.54, p=0.01). Adjustiert für Confounder.

10.1186/1471-244x-14-136 View study →
A Roberts et al. · 2025 · Psychiatry research
3 citations
Medicinal cannabis in the management of anxiety disorders: A systematic review.
Mixed Systematic Review

Systematische Review zu medizinischem Cannabis bei Angststörungen; k=57 Studien (40% Kohorten, 30% RCTs, 18% Querschnitt, 12% qualitative Designs). Unter den 13 hochwertigsten Studien zeigten 70% (n=9) positive Verbesserungen bei GAD, SAD und PTBS; 30% (n=4) negative Ergebnisse bei OCD, Trichotillomanie, Prüfungsangst und SAD. Über 90% aller Studien berichteten positive Outcomes für CBD- und THC-basiertes Cannabis. MASTER-Score: 62,9/100 (hohes Bias-Risiko durch unzureichendes Reporting). 53% (n=30) der Studien omittierten oder verwendeten selbstberichtete Daten zu Form/Dosierung.

10.1016/j.psychres.2025.116552 View study →

The impediment to action advances action. — Marcus Aurelius